The Complete Peptide Guide

Peptides are short chains of amino acids, smaller than proteins but with similar biological activity. They're popular because they can trigger specific effects in the body like appetite suppression (GLP-1s), tissue healing (BPC-157), or skin rejuvenation (GHK-Cu). Some are FDA-approved medications, while others are sold as "research chemicals."

It depends on the peptide. FDA-approved peptides like semaglutide require a prescription. Non-FDA-approved peptides are typically sold as "research chemicals not for human consumption", this is a legal gray area. You can legally purchase them, but using them for human consumption technically violates their labeling.

FDA-approved peptides have established safety profiles from clinical trials. Research peptides have limited human safety data, most evidence comes from animal studies. Key risks include: contamination from unregulated sources, unknown long-term effects, and unpredictable interactions when "stacking" multiple peptides.

FDA-approved peptides (like semaglutide/tirzepatide) have undergone rigorous human clinical trials proving safety and efficacy. Research peptides (like BPC-157, TB-500) have promising animal data but limited human trials. The quality control, purity standards, and legal protections differ dramatically between these categories.

Look for: third-party testing with Certificates of Analysis (COAs), established reputation in the community, transparent manufacturing information, and reasonable pricing (too cheap often means poor quality). Avoid sources making medical claims, as legitimate sellers market as "research purposes only."

Many peptides require subcutaneous injection. While some people do self-inject, this carries risks: improper reconstitution can degrade the peptide, contamination risks from improper technique, and no medical oversight for side effects. FDA-approved peptides from pharmacies come in pre-filled pens designed for home use.

No, and this is worth getting right because the claim is everywhere. On 15 April 2026 the FDA removed twelve peptides from Category 2 of its 503A list, the category reserved for substances it has flagged with identified safety risks. That removed a prohibition designation. It did not grant permission. The substances returned to an unapproved, unscheduled baseline: not explicitly barred, not authorized either, and still not on the 503A list of bulk substances compounding pharmacies may legally use. Two details make the "legalized" framing worse. First, they came off the list because the nominations were withdrawn and HHS directed it, not because the FDA reviewed the evidence and concluded they were safe. Second, none of them is an FDA-approved drug, so "prescribed legally" was never the situation being restored. If the FDA completes rulemaking to add some of them to the 503A list, that will be a genuine change, and it has not happened.

This is in active flux, and it is the single most misreported thing in this category. In 2023 the FDA placed around twenty peptides in Category 2 of its 503A list, flagging safety concerns and effectively blocking them from compounding. It removed five in September 2024 (AOD-9604, CJC-1295, ipamorelin, thymosin alpha-1, selank). Then on 15 April 2026, following withdrawal of the nominations and direction from HHS Secretary Robert F. Kennedy Jr., twelve more came off Category 2: BPC-157, LL-37, DiHexa, DSIP, epitalon, injectable GHK-Cu, KPV, PEG-MGF, melanotan II, MOTS-c, semax, and TB-500. Here is the part that gets reported wrongly: coming off Category 2 is not permission. It removed an explicit prohibition designation and returned these substances to an unapproved, unscheduled baseline. It did not put them on the 503A list of substances pharmacies may use, and the nominations were withdrawn rather than the FDA reassessing the safety evidence. An advisory committee then recommended six of them (BPC-157, KPV, TB-500, MOTS-c, semax, epitalon) for that list on 23-24 July 2026 and voted against DSIP, but advisory votes are non-binding and the FDA has not completed the rulemaking that would actually change the law. The other five, including LL-37 and injectable GHK-Cu, are not scheduled for review until before the end of February 2027. FDA-approved peptides like semaglutide, tirzepatide, tesamorelin, and PT-141 are unaffected and remain available by prescription.